卡瑞利珠单克隆抗体联合阿帕替尼治疗中晚期肝细胞癌患者疗效及预后分析*

doi:10.3969/j.issn.1672-5069.2024.01.025

摘要/Abstract

摘要： 目的探讨应用卡瑞利珠单克隆抗体联合阿帕替尼治疗中晚期肝细胞癌(HCC)患者的疗效及其影响预后的因素。方法 2019年6月～2021年10月新疆医科大学第一附属医院收治的中晚期HCC患者117例,其中联合治疗组65例接受卡瑞利珠单克隆抗体联合阿帕替尼治疗,另52例接受阿帕替尼治疗。根据mRECIST评价肿瘤治疗效果,采用Kaplan-Meier法分析无进展生存期(PFS)及其影响因素,应用多因素COX回归分析影响PFS的因素。结果随访12月,联合治疗组客观缓解率(ORR)和疾病控制率(DCR)分别为44.7%和66.2%,显著高于阿帕替尼治疗组的15.4%和42.3%(P<0.05);在治疗3个月末,联合治疗组血小板(PLT)计数为81.0(51.5,145.5)×10⁹/L,显著低于单药治疗组[107.0(69.5,191.0)×10⁹/L,P<0.05];联合治疗组PFS为10.6(95%CI:9.986～11.16)个月,显著长于阿帕替尼组的7.9(95%CI:6.84～8.944)个月(Log-rank=12.807,P<0.05);体力活动状态(PS)、Child-Pugh评分、CNLC分期、有无肝硬化、门脉癌栓和肝动脉化疗栓塞术(TACE)是影响PFS的因素(P<0.05);COX多因素回归分析显示,Child-Pugh B级(HR=2.379,P=0.021)和伴有门脉癌栓(HR=3.481,P=0.003)是影响中晚期HCC患者PFS的独立危险因素,而TACE(HR=0.528,P=0.034)则是独立保护因素。结论应用卡瑞利珠单克隆抗体联合阿帕替尼治疗中晚期HCC患者能有效提高疗效,延长生存时间。对于肿瘤负荷较大的患者,加用TACE联合治疗可以帮助临床获益。

关键词: 肝细胞癌, 卡瑞利珠单克隆抗体, 阿帕替尼, 治疗, 晚期

Abstract: Objective This clinical trial was conducted to investigate the efficacy of camrelizumab and apatinib combination in the treatment of patients with advanced hepatocellular carcinoma (HCC). Methods A total of 117 patients with advanced HCC were admitted to the first affiliated Hospital of Xinjiang Medical University between June 2019 and October 2021, and 65 patients were treated with camrelizumab and apatinib combination, and 52 patients were treated by apatinib alone. All patients were followed-up for one year. The therapeutic efficacy was evaluated according to mRECIST, the progression-free survival (PFS) and its influencing factors were analyzed by Kaplan-Meier method, and the prognostic factors of PFS were analyzed by multivariate COX regression. Results The objective remission rate (ORR) and the disease control rate (DCR) in patients with combination treatment were 44.7% and 66.2%, both significantly greater than 15.4% and 42.3% in the apatinib-treated patients (P<0.05); at the end of three-month treatment, the blood platelet count in patients with combination treatment was 81.0(51.5, 145.5)×10⁹/L, much lower than [107.0(69.5, 191.0)×10⁹/L P<0.05] in patients with apatinib treatment alone; the PFS in patients with combination treatment was 10.6 (95%CI:9.986-11.16) months, significantly longer than 7.9 (95%CI:6.84-8.944) months in the apatinib-treated group (Log-rank=12.807,P<0.05); the performance status (PS), Child-Pugh score, CNLC stage, liver cirrhosis, portal vein tumor thrombus and transarterial chemoembolization (TACE) were the prognostic factors impacting PFS, and the multivariate COX regression analysis showed that the Child-Pugh grade B (HR=2.379,P=0.021) and portal vein tumor thrombus (HR=3.481,P=0.003) were the independent risk factors for PFS, while the TACE (HR=0.528, P=0.034) was an independent protective factor for PFS in patients with advanced HCC. Conclusion The combination of camrelizumab and apatinib in treating patients with advanced HCC could effectively improve the clinical efficacy, with an obvious prolonged survival period. For patients with high tumor load, the auxiliary TACE might help raise better clinical benefits.

Key words: Hepatocellular carcinoma, Camrelizumab, Apatinib, Therapy, Advanced

叶萌萌, 邓泽润, 张韬. 卡瑞利珠单克隆抗体联合阿帕替尼治疗中晚期肝细胞癌患者疗效及预后分析^*[J]. 实用肝脏病杂志, 2024, 27(1): 96-100.

Ye Mengmeng, Deng Zerun, Zhang Tao. Improved benefit of camrelizumab and apatinib combination in the treatment of patients with advanced hepatocellular carcinoma[J]. Journal of Practical Hepatology, 2024, 27(1): 96-100.

参考文献

[1] 中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2022年版). 肿瘤防治研究, 2022, 49(3): 251-276.
[2] Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol, 2019, 16(10): 589-604.
[3] Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol, 2009, 10(1): 25-34.
[4] Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008, 359(4): 378-390.
[5] Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol, 2018, 19(7): 940-952.
[6] El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet, 2017, 389(10088): 2492-2502.
[7] Kudo M. Scientific rationale for combined immunotherapy with PD-1/PD-L1 antibodies and VEGF inhibitors in advanced hepatocellular carcinoma. Cancers (Basel), 2020, 12(5): 1089.
[8] Simcock R, Wright J. Beyond performance status. Clin Oncol (R Coll Radiol), 2020, 32(9): 553-561.
[9] Lencioni R, Llovet JM. Modified recist (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis, 2010, 30(1): 52-60.
[10] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin, 2020, 70(1): 7-30.
[11] Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health, 2018, 6(5): e555-e567.
[12] Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol, 2022, 76(4): 862-873.
[13] Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol, 2021, 22(7): 977-990.
[14] Xu J, Shen J, Gu S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial. Clin Cancer Res, 2021, 27(4): 1003-1011.
[15] Qin S, Chan LS, Gu S, et al. Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase III trial. Ann Oncol, 2022, 33(7): S1401-S1402.
[16] 中国临床肿瘤学会(CSCO). 原发性肝癌诊疗指南(2022年). 北京: 人民出版社, 2022: 88-89.
[17] Bai DS, Zhang C, Chen P, et al. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep, 2017, 7(1): 12870.
[18] Zheng Y, Zhu M, Li M. Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma. J Cancer Res Clin Oncol, 2020, 146(10): 2439-2446.
[19] Xu LX, He MH, Dai ZH, et al. Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma. Ann Oncol, 2019, 30(6): 990-997.
[20] Nie M, Liu Y, Li XX, et al. PD-1/PD-L pathway potentially involved in ITP immunopathogenesis. Thromb Haemost, 2019, 119(5): 758-765.

卡瑞利珠单克隆抗体联合阿帕替尼治疗中晚期肝细胞癌患者疗效及预后分析^*

Improved benefit of camrelizumab and apatinib combination in the treatment of patients with advanced hepatocellular carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈从新, 陈曦, 王莉苹, 赵秋香, 刘颖, 周海洋. 糖皮质激素在肝病治疗中的应用[J]. 实用肝脏病杂志, 2024, 27(3): 321-323.
[2]	赵玉雯, 朱传龙. 肝硬化营养不良及肌少症治疗研究进展[J]. 实用肝脏病杂志, 2024, 27(3): 324-328.
[3]	罗良德, 任成果, 王守军, 邓颖春. 恩替卡韦联合多烯磷脂酰胆碱治疗慢性乙型肝炎合并NASH患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 333-336.
[4]	周安琪, 孟舒婷, 吴应冬, 张弦. 接受核苷(酸)类似物抗病毒的慢性乙型肝炎患者发生低病毒血症危险因素分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 337-340.
[5]	程艳洁, 王鹏飞, 李峻. 水飞蓟素联合复方蛋氨酸胆碱治疗酒精性肝炎患者疗效及其对血清肝纤维化指标的影响^*[J]. 实用肝脏病杂志, 2024, 27(3): 349-352.
[6]	徐秋萍, 黄彬, 陈敏, 余静. 泼尼松与泼尼松联合硫唑嘌呤治疗自身免疫性肝炎患者外周血MDSCs百分比、肝组织白细胞介素-35和血清CD38水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(3): 374-377.
[7]	姜正伟, 周冰清, 汤洁, 蒋蓓莉. 血清抗糖蛋白210抗体阳性的原发性胆汁性胆管炎患者临床特征分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 378-381.
[8]	李菊兰, 张华堂, 郑怡娟, 余雪平, 邓勇, 苏智军. 恩替卡韦联合扶正化瘀片治疗乙型肝炎肝硬化患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 402-405.
[9]	蔡峻岭, 苏立, 郝丽, 赵敏, 裴旭东. 基于索磷布韦的直接抗病毒药物治疗丙型肝炎肝硬化患者疗效评价^*[J]. 实用肝脏病杂志, 2024, 27(3): 406-409.
[10]	倪裕丰, 倪国英, 杨志勇. 肝细胞癌组织BCLAF1和TCF3 RNA水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(3): 418-421.
[11]	梅文娟, 李新, 张昊月. 超声造影时间-强度曲线相关参数鉴别诊断肝细胞癌与转移性肝癌价值研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 430-433.
[12]	罗珂, 丁莉, 刘美. 肝细胞癌患者癌组织TTF-1、p53、p63表达变化及其对术后生存的影响^*[J]. 实用肝脏病杂志, 2024, 27(3): 434-437.
[13]	闫振, 赵博文, 林国英, 殷和良. 影像学三维可视化技术指导肝切除术治疗肝细胞癌患者临床疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 438-441.
[14]	王倩文, 胡琳琳, 徐运军. 动态增强MRI联合血清SPINK1水平诊断原发性肝癌价值研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 442-445.
[15]	李玮健, 刘昕, 舒红艳. 超声引导下聚桂醇与无水乙醇注射硬化治疗肝囊肿患者疗效比较研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 450-453.